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Introduction: Intraparenchymal injections of the immunotoxin 192-IgG-saporin into medial septum and nucleus
basalis magnocellularis causes a selective depletion of basal forebrain cholinergic neurons. Thus, it represents a valid
model to mimic a key component of the cognitive deficits associated with aging and dementia. Here we administered
donepezil, a potent acetylcholinesterase inhibitor developed for treating Alzheimer’s disease, 15 days before
192-IgG-saporin injection, and thus we examined donepezil effects on neurodegeneration and cognitive deficits.
Methods: Caspase-3 activity and cognitive performances of lesioned rats pre-treated with donepezil or saline
were analyzed and compared to the outcomes obtained in pre-treated sham-lesioned rats.
Results: Cholinergic depletion increased hippocampal and neocortical caspase-3 activity and impaired working
memory, spatial discrimination, social novelty preference, and ultrasonic vocalizations, without affecting anxiety
levels and fear conditioning. In lesioned animals, donepezil pre-treatment reduced hippocampal and neocortical
caspase-3 activity and improved working memory and spatial discrimination performances and partially rescued
ultrasonic vocalizations, without preventing social novelty alterations.
Conclusions: Present data indicate that donepezil pre-treatment exerts beneficial effects on behavioral deficits
induced by cholinergic depletion, attenuating the concomitant hippocampal and neocortical neurodegeneration.Introduction
Experimental and clinical evidence supports the hypoth-
esis that the loss of basal forebrain (BF) cholinergic neu-
rons and the consequent reduction of acetylcholine (ACh)
synthesis and release significantly contribute to the cogni-
tive impairment of aging disorders, such as mild cognitive
impairment (MCI) and Alzheimer’s disease (AD) [1-3].
Acetylcholinesterase inhibitors (AChE-Is) such as donepe-
zil prevent the hydrolysis of the residual ACh in the brain
and represent the best pharmacological tool to attenuate
cognitive disturbances in patients with mild to moderate
AD [4,5]. AChE-Is are currently used as a symptomatic
treatment to improve or at least maintain central choliner-
gic function [6,7].* Correspondence: debora_cutuli@yahoo.it
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reproduction in any medium, provided the orTo date, besides the research of new drugs able to com-
bat age-related cognitive decline, the protection of neurons
from damage and death associated with neurodegenerative
disorders is a major challenge in neuroscience. The concept
of neuroprotection has found increasing acceptance in
neurology during the past decade and includes interven-
tions aimed to slow or even halt the progress of neuronal
degeneration. Interestingly, there is growing evidence that,
beyond allowing alleviation of cognitive symptoms, AChE-
Is produce effective neuroprotection [7]. In fact, it has been
shown that AChE-Is protect against glutamate excitotoxi-
city, neuronal damage and amyloid β (Aβ) neurotoxicity.
Furthermore, many studies have shown that they induce
upregulation of nicotinic ACh receptors (nAChRs) [8-18].
Importantly, α4 and α7 nAChRs play a crucial role in
AChE-I-mediated neuroprotection, mainly through the
involvement of the phosphatidylinositol 3-kinase (PI3K)
pathway [8,17]. Unfortunately, few in vivo studies have
examined AChE-I neuroprotective action [7]. Although
a lot of studies have demonstrated the symptomatic effects
of donepezil in models of aging and dementia [19-25], atd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neuroprotective effects by administering donepezil only be-
fore (not during) behavioral testing [12-14,26,27]. Namely,
injecting donepezil before a hypoxic insult has been shown
to alleviate hypoxia-induced neurodegeneration and behav-
ioral impairment [12], and, similarly, administrating done-
pezil before Aβ injection was demonstrated to block lipid
peroxidation and learning deficits [13]. In both studies,
donepezil neuroprotective effects appeared to be medi-
ated by the activation of the σ1 receptor, a protein involved
in modulation of intracellular Ca2+ mobilization, oxida-
tive stress and neurotransmitter response. Furthermore,
donepezil pre-treatment significantly prevented isoflurane-
induced cholinergic degeneration and spatial memory
impairment in aged mice [27] and attenuated okadaic
acid–induced memory impairment, mitochondrial dys-
function and apoptotic cell death [26]. Donepezil pre-
treatment also prevented streptozotocin (STZ)-induced
memory deficits, oxidative stress, mitochondrial dys-
function and caspase-3 activity through the specific in-
volvement of nAChRs [14].
In the light of these studies, it seemed interesting to as-
sess the neuroprotective properties of long-term pre-le-
sion donepezil treatment in a rat model of BF cholinergic
depletion induced by 192-immunoglobulin G (IgG)-
saporin (Sap) injection. The resulting permanent and se-
lective Sap-dependent loss of cholinergic BF neurons
mimics neuropathological features and cognitive impair-
ments associated with MCI and AD. In fact, Sap selectively
causes death of cholinergic cells by inhibiting ribosomal
protein synthesis when it is taken up into cells expressing
the low-affinity neurotrophin receptor p75 [28]. In the past
two decades, the availability of Sap allowed studying the
role of BF cholinergic system in several cognitive functions
and its implications in aging and dementia [29].
In the present study, we focused on the neuroprotec-
tive action of donepezil by investigating the influence of
donepezil pre-treatment on cognitive deficits and neur-
onal impairment induced by intraparenchymal Sap injec-
tions into the medial septum (MS) and nucleus basalis
magnocellularis (NBM). To achieve this aim, cognitive
performance and caspase-3 activity levels of cholinergi-
cally depleted rats pre-treated with donepezil or saline
were compared with those of pre-treated sham-lesioned
animals. Cognitive function was analyzed by means of a
wide battery of behavioral tests, including elevated plus
maze (EPM), open field with objects (OF), radial arm
maze (RAM), sociability and preference for social novelty
test (PSNT) and fear conditioning (FC) with ultrasonic
vocalization (USV) recording. The low-frequency USVs
reflect a negative affective state [30,31] and are positively
correlated with the aversiveness of the situation [32]. After
behavioral testing, neurodegeneration was analyzed by
measuring caspase-3 activity in the hippocampus andneocortex, projection areas of the lesion sites. In fact,
caspase-3 is the main effector caspase, whose localized
activation can trigger synaptic loss, causing cognitive
and behavioral deficits [33], whereas strong activation
leads to switching on of the apoptotic cascade. Because
the increase in caspase-3 activity has been proposed as an
early neurodegenerative event in AD progression [34-36],
its quantification might be useful in evaluating the efficacy
of neuroprotective pharmacological treatment.
Methods
Study animals
Male Wistar rats (about 300 g and 2.5 months of age)
kept in standard laboratory conditions (08.00:20.00 light,
food and water ad libitum and controlled humidity and
temperature) were used in the experiments. The animals
were maintained according to the guidelines for ethical
conduct developed by the European Union directive of
22 September 2010 (2010/63/EU). The study was approved
by the local ethics committee of the IRCCS Fondazione
Santa Lucia. Rats subjected to behavioral testing were
randomly assigned to the following experimental groups:
(1) donepezil-treated sham-lesioned (Don-Sham) rats
(n = 7), which were treated with donepezil and
then sham-lesioned; (2) donepezil-treated Sap-lesioned
(Don-Sap) rats (n = 8), which were treated with donepezil
and then Sap-lesioned; (3) saline-treated Sap-lesioned
(Sal-Sap) rats (n = 8), which were treated with saline
(NaCl 0.9%) and then Sap-lesioned; and (4) saline-treated
sham-lesioned (Sal-Sham) rats (n = 12), which were
treated with saline and then sham-lesioned. This group
encompassed six intact rats treated with saline and six
rats pre-treated with saline and then sham-lesioned.
The behavioral performance of the two groups was not
statistically different in all the following behavioral
parameters (multivariate analysis of variance (group ×
parameter): group: F1,10 = 0.01, P = n.s.; parameter:
F37,370 = 120.79, P < 0.000001; and group × parameter:
F37,370 = 1.25, P = n.s.; Additional file 1). These animals
were pooled in the Sal-Sham group. At the end of behav-
ioral testing, all rats were killed to verify the lesion by
choline acetyltransferase (ChAT) immunohistochemis-
try on the lesion sites (MS and NBM). Furthermore, an
additional three rats per group were prepared to verify
ChAT levels in target areas of cholinergic projections
(hippocampus and neocortex) and synaptic impairment.
In these rats, ChAT densitometry and caspase-3
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solved in 0.5 ml of 0.9% NaCl solution. The same volume
of saline without the drug was administered daily to the
animals used as controls (Sal-Sham and Sal-Sap). Pre-
treatment started 15 days before Sap or sham lesions were
created and was stopped after the surgery (Figure 1). The
donepezil dosage was chosen on the basis of information
from previous in vivo studies [12,13].
Surgery
All rats were anesthetized with a mixture of tiletamine/
zolazepam (50 mg/kg Zoletil 100 i.p.; Virbac s.r.l., Milan,
Italy) and xylazine (10 mg/kg Rompun i.p.; Bayer s.p.a.,
Milan, Italy). In the animals to be lesioned, the immuno-
toxin 192 IgG-Sap (Chemicon International, Harrow, UK)
was bilaterally injected through a 10-μl Hamilton syringe
in the MS (dosage: 0.5 μg/side 192 IgG-Sap; coordinates:
anteroposterior (AP) = +0.45 mm (from the bregma);
mediolateral (ML) = ±0.6 mm (from the midline); and
dorsoventral (DV) = −7.2 mm (from the dura) [36]) and in
the NBM (dosage: 0.4 μg/side; coordinates: AP = +1 mm
(from the bregma); ML = ±2.3 mm (from the midline);
and DV = −8 mm (from the dura) [37] with doses and co-











Figure 1 Experimental design. Diagram describing the global timing of t
pre-treatment (donepezil or saline), lesioned (192-IgG-saporin, Sap, or sham
behavioral testing, are indicated. ChAT, Choline acetyltransferase; Don-Sap,
sham-lesioned rats; IgG, immunoglobulin G; Sal-Sap, saline-treated Sap-lesio192 IgG-Sap diluted in PBS (1 μg:1 μl) was injected at a
rate of 0.1 μl/min. At the end of administration, the needle
was left in situ for five minutes. In the remaining rats, only
PBS solution was injected.
Behavioral testing
As shown in Figure 1, 2.5 weeks after the surgery (time
required to reach a stable and permanent loss of cholin-
ergic neurons using Sap [28]), all rats were subjected to
the following tests: EPM, to assess anxiety levels; OF, to
evaluate the ability to develop spatial and discriminative
competencies; RAM, to analyze spatial working memory;
sociability test, to analyze social motivation; PSNT, to
evaluate social novelty discrimination; and contextual and
tone FC with USV recordings, to analyze acquisition of
aversive learning and emotional competencies. A pseudo-
random order of test administration was used with FC
always being the last test, given its high stress levels.
Elevated plus maze
The maze raised 90 cm above the ground was formed by
a wooden structure in the shape of a cross with four
50 cm × 10 cm arms. The north and south arms were




he experimental design of the four groups. Data derived from
), caspase-3 and choline acetyltransferase analyses, as well as
donepezil-treated Sap-lesioned rats; Don-Sham, donepezil-treated
ned rats; Sal-Sham, saline-treated sham-lesioned rats.
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quency of entries into the open and closed arms, total
time spent in the open and closed arms and number of
defecations [20].
The parameters taken into account were: frequency of
entries in the open and closed arms; total time spent in
the open and closed arms; number of defecations [20].Open field with objects
The apparatus consisted of a circular arena (diameter
140 cm) delimited by a 30-cm-high wall. During session
1 (S1), each rat was allowed to move freely in the empty
open field and the baseline activity level was measured.
During S2 to S4 (habituation phase), four objects were
placed in a square arrangement in the middle annulus
of the arena and a fifth one was placed in the central
area. In S5 and S6 (spatial change), the spatial configur-
ation was changed by moving objects 2 and 5 so that the
initial square arrangement was changed to a polygon-
shaped configuration without any central object. During S7
(novelty), the configuration was modified by substitut-
ing one object with another new one. Sessions lasted six
minutes, and intersession intervals were three minutes
long. All testing was recorded by a video camera whose
signal was relayed to a monitor and to an image analyzer
(EthoVision, Noldus Information Technology, Wageningen,
The Netherlands). The parameters taken into account were
total and peripheral distances traveled in S1, time spent
contacting the objects, frequency of rearing, motionless
time and number of defecations [20,39].Radial arm maze
The apparatus consisted of a central platform (30-cm
diameter) from which eight arms (12.5 cm wide × 60 cm
long) radiated like the spokes of a wheel. A food well
(5-cm diameter, 2-cm depth) was located at the end of
each arm [20]. A 40-W red light bulb provided the
only source of illumination in the testing room. Testing
was performed between 09:00 and 17:00 hours. After a
habituation phase, all rats (whose food was restricted to
decrease their weight by approximately 15%) were sub-
jected to the RAM full-baited procedure in which all
arms were baited with a piece of Purina chow (Purina
Mills, Gray Summit, MO, USA) with the goal of having
the rats collect the eight rewards in a maximum of 16
entries. The animals were subjected to two trials daily
for five consecutive days. The intersession interval was
four hours. The parameters taken into account were
percentage of total errors (number of revisited arms
divided by total number of visits × 100), mean spatial
span (longest sequence of correctly visited arms in each
session) and perseverations (sum of consecutive entries
in the same arm or in a fixed sequence of arms).Sociability and preference for social novelty test
The apparatus consisted of a white rectangular three-
chamber wooden box (150 × 40 × 40 cm). The central
chamber was 30 cm long, and the two lateral chambers
were 60 cm long. The three chambers were divided by
two transparent Plexiglas walls with an open middle door
(height 10 cm, width 8 cm), which allowed free access
to each lateral chamber. Each lateral chamber con-
tained a small plastic cage (18-cm diameter) with mesh-
like holes in which stranger rats were confined for social
interaction.
The test comprised 3 sessions: Habituation, Sociability
and PSNT. During the habituation, each rat was allowed
to freely move in the apparatus for 10 min. During
Sociability, an unfamiliar juvenile (35 to 45 days old)
male conspecific (Stranger 1) was placed inside the small
cage in one of the lateral chambers (randomly selected
and counterbalanced for each group). The experimental
rat was placed in the apparatus and it was allowed to
freely explore the three chambers and contact the small
cages for ten minutes.
During PSNT, another unfamiliar rat (stranger 2) was
placed inside the plastic cage of the opposite lateral
chamber that had been empty during the Sociability
session. The experimental rat was allowed to move freely
and contact the plastic cages housing the strangers for
ten minutes. Inter-session intervals lasted three mi-
nutes. Rats’ behavior was recorded by a video camera
mounted on the ceiling. The resulting video signal was
relayed to a monitor and to an EthoVision image
analyzer. The parameters analyzed in each lateral
chamber were frequency of entries, total duration (in
seconds) and total distance traveled (in centimeters).
Context and tone fear conditioning
The apparatus consisted of a 21 × 21 × 49 cm condition-
ing chamber (model 7532; Ugo Basile, Comerio, Italy).
Chamber walls were made of gray Plexiglas, and the
ceiling was made of transparent Plexiglas to allow video
recording. The grid floor (steel pieces spaced by 1.5 cm)
was connected to a shock generator scrambler (condi-
tioner 7531; Ugo Basile).
The FC test encompassed three sessions: training,
context and tone. During training session, following a
120 seconds of acclimation to the conditioning appar-
atus (baseline), three trials consisting of the 30-second
tone exposure (2 kHz, 90 dB) were carried out. The
last 2 seconds of each tone were paired with a 1-mA
foot shock. Tone- and shock-free 60-second inter-trial
intervals were used.
After 24 hours, rats were placed for 240 seconds in
the training chamber (context test). After 4 hours, the
rats were submitted to a tone test in a white Plexiglas
box (21 × 18 × 45 cm) with black stripes applied on the
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tone identical to that used in the training session was
sounded without any shock (tone test).
During training, context and tone tests, the rats’ be-
havior was recorded by a video camera mounted on the
ceiling. The resulting video signal was relayed to a moni-
tor and to an EthoVision image analyzer. In addition,
22-kHz USVs were recorded [38,40].
Behavioral parameters taken into account were frequency
and duration of freezing (behavioral immobility, except for
respiration movements) and number of defecations.
USVs were collected via an ultrasound microphone
(UltraSoundGate CM16; Avisoft Bioacoustics, Berlin,
Germany) placed through a hole in the middle of the
test chamber roof approximately 21 cm above the shock
floor. The microphone was sensitive to 15 to 180 kHz
frequencies with a flat frequency response (±6 dB) be-
tween 25 and 140 kHz. It was connected by an Ultra-
SoundGate USB audio device to a personal computer,
which recorded data at 250,000 Hz in 16-bit format and
stored as .wav files for subsequent analysis. Sound files
were transferred to SASLab Pro (version 5.2; Avisoft
Bioacoustics) for sonographic analysis and a fast Fourier
transform (FFT) was performed (512 FFT length, 100%
frame, Hamming window and 75% time window over-
lap). USV parameters taken into account were number
of calls emitted, peak amplitude and frequency, frequency
modulation and call duration.
Histological analyses
At the end of behavioral testing, the animals were
deeply anesthetized and transcardially perfused with sa-
line, followed by 4% paraformaldehyde and 0.1% glutar-
aldehyde in PBS (4°C, pH 7.5). Brains were removed and
cryoprotected in 30% buffered sucrose and cut on a
freezing microtome. The anterior part of the brain was
cut into coronal sections of 40 μm and stored for ChAT
immunohistochemistry.
Choline acetyltransferase immunohistochemical staining
Sections (40 μm) immunostained for ChAT were prein-
cubated in PBS at 4°C, then in 0.4% Triton X-100 in PBS
and finally in 0.1% Triton X-100 plus 1% bovine serum
albumin (Sigma-Aldrich, St Louis, MO, USA) plus nor-
mal goat serum (NGS; Vector Laboratories, Burlingame,
CA, USA) in PBS. Sections were incubated for 16 hours
at 4°C with 0.1% Triton X-100 and NGS in PBS with the
primary antibody for ChAT diluted 1:1,000 (Chemicon
International). Subsequently, sections were incubated
with biotinylated secondary antibody (goat anti-rabbit IgG-
biotin conjugate) and 3% NGS (Kit Elite PK-6101; Vector
Laboratories) in PBS for 10 minutes at room temperature.
Staining was visualized with 0.05% diaminobenzidine
and ammonium nickel(II) sulfate (Sigma-Aldrich Chemie,Steinheim, Germany) after incubation with avidin and
biotinylated peroxidase (Kit Elite PK-6101). The sec-
tions were then rinsed in PBS. Stained sections were
mounted on slides, dehydrated and coverslipped. To ex-
clude artefacts, in each case some random sections were
processed as previously described. The only difference
was the absence of the primary antibody.
Biochemical analyses
Total homogenate preparation from hippocampal and
neocortical tissues
After the animals were decapitated, hippocampal and neo-
cortical tissues were dissected and homogenized in lysis
buffer (320 mM sucrose, 50 mM NaCl, 50 mM Tris-HCl
(pH 7.5), 1% Triton X-100, 0.5 mM sodium orthovanadate,
5 mM β-glycerophosphate, proteases inhibitors), then incu-
bated on ice for 30 minutes and centrifuged at 13,000 g
for 10 minutes. The total protein content of the resulting
supernatant was determined by the Bradford assay method.
Immunoblot analysis and antibodies
Proteins were subjected to SDS-PAGE and electroblotted
onto a polyvinylidene fluoride membrane. Immunoblot
analysis was performed using a chemiluminescence de-
tection kit. The relative levels of immunoreactivity were
determined by densitometry using ImageQuant 5.0 software.
Antibodies to anti-ChAT were purchased from Chemicon
International (AB143), and anti-actin clone EP184E rabbit
monoclonal antibody was obtained from EMD Millipore
(04-1040; Billerica, MA, USA).
Fluorometric assay of caspase-3 activity
Total hippocampal and neocortical tissue was homoge-
nized in lysis assay buffer (100 mM 2-[4-(2-hydroxyethyl)
piperazin-1-yl]ethanesulfonic acid (pH 7.4), 0.1% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate
(wt/vol), 1 mM ethylenediaminetetraacetic acid, 10 mM
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride) and
lysed by freezing in liquid N2 and thawing at 37°C three
times. After centrifugation at 11,500 g for 5 minutes, the
protein concentration of resulting supernatant was deter-
mined and the same amount of protein was incubated at
37°C in lysis assay buffer containing 50 μM caspase-3
substrate II, fluorogenic (Ac-DEVD-AMC; Calbiochem,
San Diego, CA, USA). The fluorescence was measured
with 380-nm excitation wavelength and 460-nm emission
wavelength.
Statistical analysis
All data were tested for normality (Shapiro-Wilk test) and
homoscedasticity (Levene’s test). Behavioral data were
analyzed using two-way analysis of variance (ANOVA;
F-statistic) (with drug and lesion as between-animal fac-
tors) or a mixed model of three-way ANOVA (with drug
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object/day/chamber as within-animal factors). Post hoc
comparisons were performed by means of Tukey’s honestly
significant difference test. When parametric assumptions
were not fully met, data transformations (angular trans-
formation for percentages) or nonparametric ANOVAs
(Kruskal-Wallis test (H-statistic) and Mann-Whitney
U test; Z-statistic) were used. Biochemical data of ChAT
levels were analyzed by Student’s t-test, and data regarding
caspase-3 activity were analyzed using the Bonferroni
multiple comparisons test. Differences were considered
significant at the P ≤ 0.05 level.
Results
Lesion verification by choline acetyltransferase
immunohistochemical staining
The presence of ChAT immunoreactive (ChAT-IR) neu-
rons in the BF projection areas was assessed by inspection
(Figures 2(a), 2(a1), 2(b), 2(b1), 2(d), 2(d1), 2(e) and 2(e1)).
Brain sections were visualized with the light microscope-
interfaced software Neurolucida (MBF Bioscience, Williston,
VT, USA). Using a 10× lens objective, ChAT-IR neurons
were assessed in the two main regions of the BF: the MS,
taking into account five 40-μm sections between 1.20 and
0.20 mm anterior to bregma, and the NBM, taking into
account eight 40-μm sections between 0.80 and 2.30 mm
posterior to the bregma [37]. Additional visual inspection
was carried out to exclude eventual degeneration of
striatal cholinergic interneurons after i.p. Sap injections in
the NBM (Figures 2(c), 2(c1), 2(f) and 2(f1)).
Lesion verification by choline acetyltransferase
immunoblot analysis
Intraparenchymal Sap injections in the NBM and MS
induced an extensive loss of ChAT-IR in the synaptic
boutons of the neocortex and hippocampus, as demon-
strated by a strong reduction in ChAT expression (Figure 3).
A comparable reduction of ChAT expression was de-
tected in the hippocampi and neocortices from both
lesioned groups (Don-Sap and Sal-Sap). Conversely, ChAT
expression was not significantly different in the sham-
lesioned groups (Sal-Sham and Don-Sham).
Hippocampal and neocortical caspase-3 activity
A significant increase in caspase-3 activity was evident in
the Sal-Sap group; however, a partial but significant rescue
was found in the Don-Sap group in both hippocampal and
neocortical extracts. Both sham-lesioned groups (Don-Sham
and Sal-Sham) exhibited similar levels of caspase-3 activity
in both hippocampal and neocortical extracts (Figure 4).
Elevated plus maze
The animals of all groups entered more frequently (F1,31 =
47.94; P < 0.000001) and spent more time (F1,31 = 200.66,P < 0.000001) in the closed arms than in the open arms.
No difference was detected in the total number of defe-
cations. Thus, neither drug nor lesion affected anxiety-
related behavior in the EPM (Additional file 2).
Open field with objects
Two-way ANOVA on total or peripheral distances trav-
eled in S1 did not reveal any significant effect of drug
or lesion. A three-way ANOVA (drug × lesion × session)
on motionless time failed to reveal any significant effect
of drug or lesion. Session effect (F6,186 = 5.01, P < 0.0001)
was significant, because motionless time increased through-
out the task in all groups. Lesion × session interaction
was also significant (F6,186 = 2.42, P = 0.03). Post hoc
comparisons revealed that both lesioned groups (Don-Sap
and Sal-Sap) tended to exhibit motionless time lower
than that of sham animals (Don-Sham and Sal-Sham) in
the final sessions of the test (S6: P = 0.02; S7: P = 0.07).
No other significant interactions were found. As ses-
sions went by, rearing (F6,186 = 28.52, P = 0.000001) and
defecation (F6,186 = 14.88, P = 0.000001) decreased with-
out any significant differences among groups. For both
parameters, no significant drug and lesion effects were
observed.
In the presence of the objects, all animals showed
habituation, as revealed by the significant session effect
(F2,62 = 42.26, P < 0.000001) of three-way ANOVA (drug ×
lesion × session) on contact times. Drug and lesion effects
and their interaction were not significant.
A three-way ANOVA (drug × lesion × object) on S5 con-
tact time revealed a significant object effect (F1,31 = 23.28,
P < 0.0001), as well as significant interactions of drug × object
(F1,31 = 14.22, P < 0.001), lesion × object (F1,31 = 8.11,
P < 0.01) and drug × lesion × object (F1,31 = 7.15, P = 0.01).
Post hoc comparisons performed on the second-order inter-
action revealed that, in S5, both sham groups (Don-Sham
and Sal-Sham), as well as the Don-Sap group, recognized
the spatial change (P < 0.01), whereas the Sal-Sap rats failed
to detect the new spatial configuration (Figure 5(a)). Drug
and lesion effects and their interaction were not significant.
A three-way ANOVA (drug × lesion × object) on S6 con-
tact time revealed a significant lesion effect (F1,31 = 24.64,
P < 0.0001), as well as significant interactions of drug × ob-
ject (F1,31 = 13.18, P = 0.001), lesion × object (F1,31 = 14.05,
P = 0.001) and drug × lesion × object (F1,31 = 9.26, P =
0.005). Post hoc comparisons on the second-order inter-
action revealed that, though Don-Sham, Sal-Sham and Don-
Sap groups did not show any preference towards displaced
objects, Sal-Sap rats continued to explore nondisplaced ob-
jects longer (P < 0.001) (Figure 5(b)). Drug and object effects
and drug × lesion interactions were not significant.
A three-way ANOVA (drug × lesion × object) on S7
contact time indicated that all animals recognized novelty,
as revealed by the significant object effect (F1,31 = 25.31,
Figure 2 (See legend on next page.)
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Figure 2 Choline acetyltransferase immunohistochemical staining. Representative photomicrographs of intraparenchimal Sap injection
effects. Images show brain sections of rats that were saline-treated, sham-lesioned (a, b and c); saline-treated, Sap-lesioned (a1, b1 and c1);
donepezil-treated, sham-lesioned (d, e and f); and donepezil-treated, Sap-lesioned (d1, e1 and f1). Coronal sections at the level of medial
septum (a, a1, d and d1), nucleus basalis magnocellularis (b, b1, e and e1) and striatal (c, c1, f and f1) regions with choline acetyltransferase
immunoreactive neurons are shown. Note the substantial absence of cholinergic neurons in both regions of the lesioned animal (a1, b1, d1 and e1)
and the substantial preservation of striatal cholinergic interneurons (c1 and f1). Lens objective: 10×. Scale bars: 50 μm.
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their interactions were not significant.
A three-way ANOVA (drug × lesion × object) on S7 con-
tact time indicated that all animals recognized novelty,
as revealed by the significant object effect (F1,31 = 25.31,
p < 0.0001) (Figure 5c). Drug and object effects, and their
interactions were not significant.Radial arm maze
As the task went by, all animals but the Sal-Sap rats
learned to correctly visit the baited arms. A three-way
ANOVA (drug × lesion × day) on total errors revealed
significant effects of lesion (F1,31 = 16.92, P < 0.001) and
day (F4,124 = 11.26, P < 0.000001), as well as a significant
second-order interaction (F4,124 = 2.75, P < 0.05). Post hoc
comparisons of the interactions revealed that Sal-Sham,
Don-Sham and Don-Sap performance was not significantly
different. Conversely, Sal-Sap rats made significantly more
errors than Sal-Sham and Don-Sap animals, as reported in
Figure 6(a). No significant drug effect or first-order interac-
tions were found.
A three-way ANOVA (drug × lesion × day) of spatial span
revealed significant day effect (F4,124 = 12.19, P < 0.000001)
and second-order interaction (F4,124 = 3.01, P < 0.05). Post
hoc comparisons indicated that Sal-Sap rats exhibited a
shorter spatial span than the animals in the Sal-Sham
and Don-Sap groups (Figure 6(b)). No significant drug
and lesion effects or first-order interactions were found.
The Kruskal-Wallis test demonstrated a significant dif-
ference among the four experimental groups (H = 9.45,
P = 0.02). In fact, a marked presence of perseverations
was evident in Sal-Sap animals when compared to Sal-Sham
rats (Z = −2.75, P = 0.007 by Mann-Whitney U test). Con-
versely, no difference in perseverations was found between
the Sal-Sham, Don-Sham and Don-Sap groups. Further-
more, the Don-Sap group tended to perseverate less
than the Sal-Sap animals (P = 0.08) (Figure 6(c)), indi-
cating a trend toward reducing perseverative behavior
in the presence of lesions with donepezil pre-treatment.Sociability and preference for social novelty test
Habituation
Three-way ANOVA (drug × lesion × chamber) on all
parameters during the habituation session allowed us toexclude any side preference, which could have consti-
tuted a bias for the following test sessions (Table 1).
Sociability
During the sociability session, all rats showed a marked
preference for the stranger 1 chamber (Figure 7(a)) re-
garding duration and distance (P < 0.000001), but not
frequency of entries (Table 1).
Preference for social novelty test
Don-Sham and Sal-Sham rats showed the predicted pref-
erence for the stranger 2 chamber (duration: P = 0.04;
distance: P = 0.01) (Figure 7(b) and Table 1). Conversely,
Don-Sap and Sal-Sap rats, although they entered the
stranger 2 chamber more frequently (P < 0.01), did not
exhibit a clear social novelty recognition, as indicated by
the time spent and distance traveled in the stranger 2
chamber (Figure 7(b) and Table 1).
Context and tone fear conditioning
Training
In all animals, postshock freezing significantly increased
in duration (F5,155 = 51.90, P < 0.000001) and frequency
(F5,155 = 22.77, P < 0.000001) in comparison to baseline
over the course of shock presentation. Neither drug nor
lesion affected duration or frequency of freezing (Figure 8
(a)). Also, no difference was detected regarding the
number of defecations. As for USVs, the Kruskal-Wallis
test demonstrated a significant difference among groups
(H = 8.21, P = 0.04). In fact, Sal-Sap rats vocalized signifi-
cantly less often than Sal-Sham rats (Z = 2.53, P = 0.02 by
Mann-Whitney U test), whereas no significant differences
were found among the remaining groups (Figure 8(a)).
Furthermore, Don-Sap rats tended to emit a higher num-
ber of USVs than Sal-Sap animals (Z =1.85, P = 0.06 by
Mann-Whitney U test). These findings indicated a trend
toward donepezil rescue of USV production in the pres-
ence of cholinergic lesion. Other USV parameters are
reported in Additional file 3.
Context test
During context testing, all animals exhibited a freezing sig-
nificantly increased in duration (F1,31 = 350.98, P < 0.000001)
and frequency (F1,31 = 87.43, P < 0.000001) compared
to baseline values, indicating effective retention of the

















































Figure 3 Choline acetyltransferase immunoblot analysis. Representative choline acetyltransferase (ChAT) immunoblots of hippocampal (hp)
and neocortical (cx) total protein extracts and densitometric quantification of changes in gray values expressed as mean ± SD. The relative fold
change in the levels of ChAT protein was normalized with respect to the level of actin, which was used as a loading control. Statistical differences
were observed between the sham and 192-IgG-saporin (Sap)-lesioned animals (n = 3/group). *P < 0.05 by t-test. Don-Sap, donepezil-treated
Sap-lesioned rats; Don-Sham, donepezil-treated sham-lesioned rats; Sal-Sap, saline-treated Sap-lesioned rats; Sal-Sham, saline-treated sham-lesioned rats.
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Figure 4 Hippocampal and neocortical caspase-3 activity.
Caspase-3 activity was revealed by a fluorometric assay in total
hippocampal and neocortical homogenates from sham and lesioned
rats (n = 3/group). The fluorometric data are expressed as mean ± SEM.
*P < 0.05, ***P ≤ 0.001 (Bonferroni multiple comparisons test).
Don-Sap, donepezil-treated Sap-lesioned rats; Don-Sham,
donepezil-treated sham-lesioned rats; Sal-Sap, saline-treated
Sap-lesioned rats; Sal-Sham, saline-treated sham-lesioned rats.
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rences were observed among groups in number of defeca-
tions. As for USVs, the experimental groups just tended to
differ (H = 6.71, P = 0.08 by Kruskal-Wallis test), with
Don-Sap and Sal-Sap lesioned rats emitting fewer USVs
than sham rats. Further USV parameters are reported in
Additional file 4.Tone test
All rats showed a significant increase in duration (F1,31 =
113.44, P < 0.000001) and frequency (F1,31 = 52.61,
P < 0.000001) of freezing during tone reexposure in
comparison to baseline values, indicating once again an ef-
fective retention of the conditioned fear response. Neither
drug nor lesion affected duration or frequency of freezing
(Figure 8(c)). No differences were observed among groups
in number of defecations. USVs were scarcely emitted by
all rats, regardless of drug and lesion conditions (H = 2.53,
P = 0.47 by Kruskal-Wallis test) (Figure 8(c)). Further USV
parameters are reported in Additional file 5.Discussion
As ACh reduction is a morphofunctional hallmark in AD,
AChE-Is, such as donepezil, are used to improve AD-
related cognitive deterioration [7]. Besides symptomatic
effects, many in vitro studies have shown that AChE-Is
might exert neuroprotective action against neurotoxic
agents, such as glutamate and Aβ plaques [8-11,15-18].
Unfortunately, only a few in vivo experiments have
confirmed AChE-I pre-lesion neuroprotective action
[12-14,26,27]. Interestingly, the present study demon-
strates a marked neuroprotective effect of donepezil
against neurodegeneration and cognitive impairment
induced by cholinergic depletion in rats. Donepezil pre-
treatment did not induce any biochemical or behavioral
modification in sham-lesioned rats, which is in accord
with the findings of Saxena et al. [14] and Su et al. [27].
We previously demonstrated that healthy rats treated
with donepezil during behavioral testing showed enhanced
memory and explorative functions in RAM and OF, as well
as reduced anxiety levels in EPM, but they did not exhibit
any improvement in spatial span, motivational levels
and associative learning [41]. Thus, although donepezil
treatment during testing is able to improve cognitive
performance even in unlesioned animals, donepezil treat-
ment before testing (pre-treatment) exerts neuroprotective
action only in the presence of lesion or insult.
Cholinergic depletion per se (Sal-Sap group) increased
hippocampal and neocortical caspase-3 activity and im-
paired working memory performance in RAM and spatial
change detection in OF, altered social discrimination per-
formance in PSNT and reduced USV production during
FC, but it did not affect anxiety levels in EPM and FC ac-
quisition. The behavioral results in our study are in line
with those reported in previous studies of memory deficits
[20,29,42,43] and impaired production of USVs [38,40,43]
and no effects on anxiety levels following 192 IgG-Sap
lesion [20,44]. Our present is the first one that explains
caspase-3 activity in the target areas of cholinergic
projections. Our results demonstrate that donepezil pre-
treatment (Don-Sap group) was able to counteract neu-
rodegeneration associated with cholinergic depletion. In
fact, hippocampal and neocortical caspase-3 levels ob-
served in Don-Sap rats were significantly decreased in
comparison to Sal-Sap. This result is in line with previ-
ous studies using donepezil pre-treatment in different
experimental paradigms. In a glutamate excitotoxicity
study, donepezil pre-treatment significantly prevented
caspase-3 activation, contributing to internalization and
downregulation of N-methyl-D-aspartate (NMDA) re-
ceptors through α7 nAChR stimulation [15]. Moreover,
following STZ lesioning, donepezil pre-treatment signifi-
cantly prevented hippocampal and neocortical caspase-3
activity [14]. The reduction of hippocampal and neocortical
caspase-3 activity by donepezil pre-treatment following
Figure 5 Open field with objects. Effects of donepezil pre-treatment and 192-IgG-saporin (Sap) lesions on open field with objects contact
time with objects during spatial change in session 5 (S5) (a), S6 (b) and novelty (S7) (c). Cholinergic depletion per se (Sal-Sap group)
significantly affected spatial discrimination abilities in S5 and S6, and donepezil pre-treatment (Don-Sap group) prevented spatial memory
deficits. In S7, all rats detected the presence of the novel object. Behavioral data are expressed as means ± SEM, and asterisks indicate post hoc
comparisons between groups. DO, Displaced object; Don-Sap, donepezil-treated Sap-lesioned rats; Don-Sham, donepezil-treated sham-lesioned rats;
FO, familiar object; NDO, non-displaced objects; NO, novel object; Sal-Sap, saline-treated Sap-lesioned rats; Sal-Sham, saline-treated sham-lesioned rats.
**P < 0.01, ***P < 0.001.
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Figure 6 Radial arm maze. Effects of donepezil pre-treatment and 192-IgG-saporin (Sap) lesions on radial arm maze total errors (a), spatial
spans (b) and perseverations (c). Donepezil pre-treatment reduced the number of errors and increased spatial span in cholinergically
depleted rats. Sal-Sham vs. Sal-Sap: #p < 0.05; ##p < 0.01; ###p < 0.001; Don-Sap vs. Sal-Sap: *p = 0.05, **p = 0.01. Don-Sap, donepezil-treated
Sap-lesioned rats; Don-Sham, donepezil-treated sham-lesioned rats; Sal-Sap, saline-treated Sap-lesioned rats; Sal-Sham, saline-treated
sham-lesioned rats.
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neuroprotective action. This effect could be ascribed to
the up-regulation of nAChRs and to the consequent
activation of the anti-apoptotic nAChR/PI3K/Akt/Bcl2
pathway, as previously hypothesized [8,17]. Namely,
several studies have demonstrated the involvement of
nAChRs in donepezil-induced neuroprotection. In fact, incontrast to the AChE-Is galantamine and tacrine, pro-
longed donepezil administration induces not only a func-
tional up-regulation but also an increased expression of
nAChRs [9,17]. Importantly, nAChR up-regulation by
donepezil is able to activate intracellular anti-apoptotic
secondary messenger systems, such as the nAChR/PI3K
pathway, that protect neurons against neuron death [17].
Table 1 Statistical comparison of behavioral responses in the habituation, sociability and preference for social novelty testa
Drug Lesion Chamber Drug × lesion Drug × chamber Lesion × chamber Drug × lesion × chamber
Parameters F (df = 1, 31) p F (df = 1, 31) p F (df = 1, 31) P F (df = 1, 31) P F (df = 1, 31) P F (df = 1, 31) P F (df = 1, 31) P
Habituation
Frequency of entries 0.01 n.s. 1.54 n.s. 3.11 n.s. 4.01 n.s. 3.01 n.s. 0.81 n.s. 0.89 n.s.
Total duration 3.62 n.s. 0.30 n.s. 0.38 n.s. 2.68 n.s. 0.01 n.s. 3.61 n.s. 2.92 n.s.
Total distance 1.90 n.s. 1.31 n.s. 0.25 n.s. 0.06 n.s. 0.15 n.s. 3.84 n.s. 3.67 n.s.
Sociability
Frequency of entries 0.01 n.s. 0.21 n.s. 2.95 n.s. 0.47 n.s. 0.01 n.s. 1.06 n.s. 0.47 n.s.
Total duration 0.04 n.s. 0.66 n.s. 57.87 <0.000001 0.04 n.s. 0.19 n.s. 0.02 n.s. 2.47 n.s.
Total distance 0.01 n.s. 0.18 n.s. 64.05 <0.000001 1.71 n.s. 0.43 n.s. 0.05 n.s. 0.91 n.s.
Preference for social novelty test
Frequency of entries 0.28 n.s. 0.01 n.s. 9.13 <0.01 2.41 n.s. 0.11 n.s. 0.18 n.s. 0.12 n.s.
Total duration 1.42 n.s. 0.20 n.s. 2.84 n.s. 0.76 n.s. 0.34 n.s. 4.21 <0.05 0.13 n.s.
Total distance 1.47 n.s. 2.18 n.s. 7.17 0.01 1.25 n.s. 0.27 n.s. 4.48 <0.05 0.48 n.s.
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Figure 7 Sociability and preference for social novelty test. Effects of donepezil pre-treatment and 192-IgG-saporin (Sap) lesions on sociability
(a) and preference for social novelty test (PSNT) (b). Although no differences among the four groups were found in the sociability test,
both groups of cholinergically depleted animals (Don-Sap and Sal-Sap) failed to exhibit an overt social novelty during PSNT. Asterisks indicate
comparisons between stranger 1 and empty/stranger 2 chamber behaviors in the four groups. **P < 0.01, ****P < 0.0001. Pound symbols
indicate comparisons between stranger 1 chamber and stranger 2 chamber behaviors in the sham groups (Don-Sham and Sal-Sham). #P < 0.05,
##P = 0.01. Don-Sap, donepezil-treated Sap-lesioned rats; Don-Sham, donepezil-treated sham-lesioned rats; Sal-Sap, saline-treated Sap-lesioned
rats; Sal-Sham, saline-treated sham-lesioned rats.
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pear to be mediated by σ1 receptor activation that result in
intracellular modulation of Ca2+ mobilization and activa-
tion of phospholipase C (PLC)/protein kinase C (PKC)
transduction pathways, attenuating the effects of mitochon-
drial or endoplasmic reticulum dysfunction [12,13].
The neuroprotective action of donepezil pre-treatment
on hippocampal and neocortical neurodegeneration could
account for the improved RAM and OF spatial perform-
ance of the pre-treated lesioned animals. Namely, in RAM,Don-Sap rats exhibited a lower number of errors and a
higher spatial span than Sal-Sap rats, reaching the mnesic
performance levels of sham-lesioned rats.
Beneficial effects of donepezil treatment on spatial work-
ing memory have been demonstrated in many experimental
models. In fact, donepezil administration reduced RAM
errors in aged or scopolamine-treated animals [45,46].
Working memory improvement has been reported in
aged mice treated with donepezil or a nicotinic agonist
































































Figure 8 Fear conditioning. Effects of donepezil pre-treatment and 192-IgG-saporin (Sap) lesions on percentage of freezing and total number of 22-
kHz fear-associated ultrasonic vocalizations (USVs) during fear conditioning (FC) training (a), context (CN) test (b) and tone (TN) test (c). All animals ac-
quired a clear freezing response during FC training and showed mnesic retention of the conditioned freezing response during CN and TN tests.
USVs were nearly totally suppressed in saline-treated Sap-lesioned rats, and donepezil pre-treatment tended to increase USV production in donepezil-treated
Sap-lesioned rats during FC training. BS, Baseline; Don-Sham, donepezil-treated sham-lesioned rats; ITI, Inter-trial interval; Sal-Sham, Saline-treated sham-le-
sioned rats. All groups: ****P < 0.00001; Sal-Sham vs. Sal-Sap: #P < 0.05.
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http://alzres.com/content/5/5/50addition, in a rat model of cholinergic depletion, done-
pezil administration (starting 1 week before and lasting
9 weeks after lesioning) mitigated procedural and work-
ing memory deficits in RAM [20]. In hypoxia and Aβ
toxicity models, donepezil pre-treatment prevented spatial
working memory deficits [12,13].
Even in OF, although cholinergic depletion per se (Sal-
Sap group) significantly affected spatial discrimination
abilities, donepezil pre-treatment (Don-Sap group) pre-
vented the spatial memory deficits. Consistent with thepreviously described impaired spatial change and preserved
novelty recognition following Sap lesions [20,42,43,47], all le-
sioned rats detected the presence of the novel object, just
as sham-lesioned rats did. In fact, though spatial change
detection implies efficient spatial mapping, novelty detec-
tion implies recognition of the salient object, thus minim-
izing the effect of the spatial and contextual factors
[38,48,49]. Interestingly, the preserved abilities in detect-
ing spatial change of Don-Sap rats reveal the specific neu-
roprotective effect of donepezil on a subtle spatial deficit
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with donepezil neuroprotective properties on spatial
mnesic performances in different brain damage models
[12-14,26,27].
In all animals, the shock exposure induced a clear
freezing response during FC training, and the condi-
tioned freezing response was retained during context
and tone tests. Although the lesion did not alter freezing
response, it decreased the concomitant production of
22-kHz USVs. Interestingly, donepezil pre-treatment dur-
ing FC training just tended to rescue the defect of fear-
associated USVs, which were nearly totally suppressed in
Sal-Sap rats. The 22-kHz USVs are part of the rodent
defensive repertoire and are emitted in response to nega-
tive experiences, such as foot-shock, presence of predators
or startling noise exposure [30-32]. These USVs are closely
associated with freezing response to actual or potential
threats and might serve as “alarm calls” for conspecificity.
There is converging evidence that Sap lesions selectively
impair the functionality of neural systems regulating USVs
[38,40,43]. Overall, our data are in agreement with the
previously described disassociation between intact freezing
response and impaired USV production in cholinergically
depleted rats [38]. Intriguingly, donepezil pre-treatment
(Don-Sap group) appeared to mitigate the USV suppres-
sion of lesioned rats during FC training. Thus, our data
corroborate the added value of USV measurement, which
provides additional information about the emotional state
of the animals in situations of coping with inescapable
aversive stimuli.
Also, social interactions and recognition of conspecifi-
city are fundamental and adaptive components of the
behavioral repertoire of numerous species. Similarly to
social transmission of food preference, social recognition
memory, which relies on the functional activation of hip-
pocampal and prelimbic cortical circuitry [50], is impaired
in the early phases of AD. Clinical trials have demon-
strated that donepezil enhances AD patients’ social inter-
action, engagement and interest [51]. On these bases, in
the present research, we investigated for the first time
donepezil pre-treatment effects on social skills using the
three-chamber test. During sociability tests, all animals
showed a clear social motivation. In fact, all of them pre-
ferred the conspecific stranger, as they spent more time
and traveled longer distances in the chamber containing
the social stimulus. These results fit with those obtained
in the sociability test described by Riedel et al. [50], but
they seem to be in disagreement with those obtained by
Savage et al. [47]. On the basis of use of a social inter-
action test, these authors reported a significant reduction
in active interactions following selective cholinergic deple-
tion of the neocortex in rats. Notably, at variance with the
social interaction test, sociability does not allow any direct
contact with the social stranger. Thus, in the presentstudy, the indirect social interactions and the scarce sa-
lience of the empty compartment featuring sociability
appear to have facilitated the exploration of the stranger
by the lesioned rats.
During PSNT, though sham rats showed a clear prefer-
ence for the novel stranger, the cholinergically depleted
animals did not exhibit overt social novelty. This result
has to be interpreted as a specific social recognition
memory deficit (as described by Riedel et al. [50]), be-
cause the OF lesioned rats did recognize the novel ob-
ject, which is in line with the findings reported by
Savage et al. [47]. Although Riedel et al. [50] reported
that donepezil administration succeeded in rescuing so-
cial memory scopolamine-induced deficits, donepezil
pre-treatment failed to prevent PSNT deficits in lesioned
rats in our present study. The different results could be
explained by methodological differences, such as treat-
ment time (acute vs. pre-treatment), behavioral protocols
(short-term vs. long-term memory) and cholinergic ma-
nipulations (scopolamine vs. Sap). Notably, hippocampal
and neocortical cholinergic deafferentation by Sap re-
sults in massive dysregulation of other neurotransmitter
systems, such as dopaminergic and glutamatergic ones,
which is known to contribute to social discrimination
[46,52,53].
Our current research reveals that donepezil pre-treatment
is able to reduce hippocampal and neocortical caspase-3
activity, thus preventing neuron degeneration, and to exert
beneficial effects on specific behavioral deficits induced
by cholinergic depletion. As indicated in previous stud-
ies, donepezil neuroprotective effects might be medi-
ated by many protective mechanisms, such as nAChR
upregulation and activation of the nAChR/PI3K path-
way [8,15,17] and the σ1 receptor/PLC/PKC pathway
[12,13]. Such effects result in a reduction of neurotox-
icity linked to NMDA receptor–mediated Ca2+ influx,
oxidative stress and caspase-3 activity [14,15]. Further-
more, donepezil exerts a protective action against Aβ
toxicity [7]. In fact, in AD patients, Aβ plaques colocalize
with nAChRs and α4 and α7 nAChR expression is reduced.
In CA1, the α4-nAChR activation causes γ-aminobutyric
acid (GABA) release from interneurons that inhibit pyr-
amidal neurons, whereas the activation of α7 nAChRs
in pyramidal neurons results in Ca2+ influx, presynaptic
neurotransmitter release and postsynaptic depolarization
[7]. Thus, Aβ interferes with nAChR activity, and the
consequent increase of glutamate and decrease of GABA
induce glutamate excitotoxicity and excitation–inhibition
imbalance, altering the fine-tuning of hippocampal firing
[6]. In AD patients, increase of caspase-3 activity has been
reported in the hippocampal and neocortical postsynaptic
density fractions [54]. Also, in the Tg2576 AD mouse
model, the increase of caspase-3 in hippocampal post-
synaptic compartment leads to alteration of synaptic
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induced cholinergic depletion mimicking Aβ interference
might cause an alteration of the excitation–inhibition
balance and produce excitotoxic damage in hippocam-
pal and neocortical neurons, which accumulate active
caspase-3. On these bases, the question is: How can
donepezil neuroprotection be exerted? By inhibiting AChE
activity, the donepezil pre-treatment might reduce the
GABAergic alterations and prevent glutamatergic exci-
totoxicity and the excitation–inhibition imbalance. In
this way, caspase-3 accumulation would be decreased,
contributing to the maintenance of hippocampal and
neocortical functioning.
Conclusions
The present results show for the first time that donepezil
pre-treatment is able to slow down the memory deficits
induced by cholinergic depletion and to reduce caspase-3
accumulation in hippocampal and neocortical areas.
Although further studies deepening understanding of the
molecular mechanisms of donepezil neuroprotective ac-
tion are needed, the present results are promising and
may lead to the development of novel strategies for pre-
vention and therapy of neurodegenerative diseases.
Additional files
Additional file 1: Figure representing sham rats’ data.
Additional file 2: Table of EPM data.
Additional file 3: Table of the main spectrographic parameters of
USVs emitted during FC training.
Additional file 4: Table of the main spectrographic parameters of
USVs emitted during the context test.
Additional file 5: Table of the main spectrographic parameters of
USVs emitted during tone test.
Abbreviations
ACh: Acetylcholine; AChE-I: Acetylcholinesterase inhibitor; AD: Alzheimer’s
disease; ANOVA: Analysis of variance; AP: Anteroposterior; Aβ: Amyloid β;
ChAT: Choline acetyltransferase; Don-Sap: Donepezil-treated immunoglobulin
G saporin-lesioned rats; Don-Sham: Donepezil-treated sham-lesioned rats;
DV: Dorsoventral; EPM: Elevated plus maze; FC: Fear conditioning; MCI: Mild
cognitive impairment; ML: Mediolateral; MS: Medial septum; nAChR: Nicotinic
acetylcholine receptor; NBM: Nucleus basalis magnocellularis; OF: Open field
with objects; PBS: Phosphate-buffered saline; PI3K: Phosphatidylinositol 3-
kinase; PKC: Protein kinase C; PLC: Phospholipase C; PSNT: Preference for
social novelty test; RAM: Radial arm maze; Sal-Sap: Saline-treated
immunoglobulin G saporin-lesioned rats; Sal-Sham: Saline-treated sham-
lesioned rats; Sap: 192 immunoglobulin G saporin; STZ: Streptozotocin;
USV: Ultrasonic vocalization.
Competing interests
The authors have no conflicts of interest to declare.
Authors’ contributions
DC, LP and MDA made substantial contributions to the conception and
design of the study. PDB performed immunotoxic lesioning and histological
analyses. DC, PC and AMT treated the animals and performed behavioral
evaluations. DO contributed to acquisition and analysis of USV data. AN
performed biochemical analyses. DC and AN undertook the statisticalanalyses. DC, LP, MDA and FDA were involved in drafting the manuscript
and revising it critically for important intellectual content. All authors
contributed to the interpretation of data and gave their final approval of the
manuscript version to be published.
Acknowledgements
Donepezil was a generous gift from Pfizer, Inc. This study was supported by
Italian Ministry of Education, Universities and Research grants (to LP and
MDA). MDA is financially supported by a grant from the Alzheimer’s
Association (NIRG-11-204588).
Author details
1IRCCS Fondazione Santa Lucia, Via del Fosso di Fiorano 64, Rome 00143, Italy.
2Department of Psychology, University of Rome “Sapienza”, Via dei Marsi 78,
Rome 00185, Italy. 3Cell Biology and Neurobiology Institute, National Research
Council, Via del Fosso di Fiorano 64, Rome 00143, Italy. 4Medical School,
Campus Bio-Medico University Molecular Neuroscience Unit, Via Alvaro del
Portillo 21, Rome 00128, Italy.
Received: 27 June 2013 Accepted: 16 October 2013
Published: 24 October 2013
References
1. Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of
geriatric memory dysfunction. Science 1982, 217:408–414.
2. Bartus RT: On neurodegenerative diseases, models, and treatment
strategies: lessons learned and lessons forgotten a generation following
the cholinergic hypothesis. Exp Neurol 2000, 163:495–529.
3. Sarter M, Bruno JP: Developmental origins of the age-related decline in
cortical cholinergic function and associated cognitive abilities. Neurobiol
Aging 2004, 25:1127–1139.
4. Galimberti D, Scarpini E: Treatment of Alzheimer’s disease: symptomatic
and disease-modifying approaches. Curr Aging Sci 2010, 3:46–56.
5. Schwarz S, Froelich L, Burns A: Pharmacological treatment of dementia.
Curr Opin Psychiatry 2012, 25:542–550.
6. D’Amelio M, Rossini PM: Brain excitability and connectivity of neuronal
assemblies in Alzheimer’s disease: from animal models to human
findings. Prog Neurobiol 2012, 99:42–60.
7. Pepeu G, Giovannini MG: Cholinesterase inhibitors and beyond. Curr Alzheimer
Res 2009, 6:86–96.
8. Akaike A, Takada-Takatori Y, Kume T, Izumi Y: Mechanisms of neuroprotective
effects of nicotine and acetylcholinesterase inhibitors: role of α4 and α7
receptors in neuroprotection. J Mol Neurosci 2010, 40:211–216.
9. Akasofu S, Kimura M, Kosasa T, Sawada K, Ogura H: Study of neuroprotection
of donepezil, a therapy for Alzheimer’s disease. Chem Biol Interact 2008,
175:222–226.
10. Arias E, Alés E, Gabilan NH, Cano-Abad MF, Villarroya M, García AG, López MG:
Galantamine prevents apoptosis induced by β-amyloid and thapsigargin:
involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004,
46:103–114.
11. Geerts H: Indicators of neuroprotection with galantamine. Brain Res Bull
2005, 64:519–524.
12. Meunier J, Ieni J, Maurice T: Antiamnesic and neuroprotective effects of
donepezil against learning impairments induced in mice by exposure to
carbon monoxide gas. J Pharmacol Exp Ther 2006, 317:1307–1319.
13. Meunier J, Ieni J, Maurice T: The anti-amnesic and neuroprotective effects of
donepezil against amyloid β25-35 peptide-induced toxicity in mice involve
an interaction with the σ1 recepto. Br J Pharmacol 2006, 149:998–1012.
14. Saxena G, Patro IK, Nath C: ICV STZ induced impairment in memory and
neuronal mitochondrial function: a protective role of nicotinic receptor.
Behav Brain Res 2011, 224:50–57.
15. Shen H, Kihara T, Hongo H, Wu X, Kem WR, Shimohama S, Akaike A,
Niidome T, Sugimoto H: Neuroprotection by donepezil against glutamate
excitotoxicity involves stimulation of α7 nicotinic receptors and
internalization of NMDA receptors. Br J Pharmacol 2010, 161:127–139.
16. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A:
Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil
against glutamate neuroto xicity in rat cortical neurons. J Pharmacol Exp
Ther 2003, 306:772–777.
17. Takada-Takatori Y, Kume T, Izumi Y, Ohgi Y, Niidome T, Fujii T, Sugimoto H,
Akaike A: Roles of nicotinic receptors in acetylcholinesterase inhibitor-
Cutuli et al. Alzheimer's Research & Therapy 2013, 5:50 Page 18 of 18
http://alzres.com/content/5/5/50induced neuroprotection and nicotinic receptor up-regulation. Biol Pharm
Bull 2009, 32:318–324.
18. Wang R, Tang XC: Neuroprotective effects of huperzine A: a natural
cholinesterase inhibitor for the treatment of Alzheimer’s disease.
Neurosignals 2005, 14:71–82.
19. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL: Chronic
treatment of old rats with donepezil or galantamine: effects on memory,
hippocampal plasticity and nicotinic receptors. Neuroscience 2000, 99:17–23.
20. Cutuli D, Foti F, Mandolesi L, De Bartolo P, Gelfo F, Federico F, Petrosini L:
Cognitive performances of cholinergically depleted rats following
chronic donepezil administration. J Alzheimers Dis 2009, 17:161–176.
21. Dong H, Csernansky CA, Martin MV, Bertchume A, Vallera D, Csernansky JG:
Acetylcholinesterase inhibitors ameliorate behavioral deficits in the
Tg2576 mouse model of Alzheimer’s disease. Psychopharmacology (Berl)
2005, 181:145–152.
22. Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML,
Warsi SP, Waller JL, Terry AV Jr: Comparison of galantamine and donepezil
for effects on nerve growth factor, cholinergic markers, and memory
performance in aged rats. J Pharmacol Exp Ther 2006, 316:679–694.
23. Marighetto A, Valerio S, Desmedt A, Philippin JN, Trocmé-Thibierge C,
Morain P: Comparative effects of the α7 nicotinic partial agonist, S 24795,
and the cholinesterase inhibitor, donepezil, against aging-related deficits in
declarative and working memory in mice. Psychopharmacol (Berl) 2008,
197:499–508.
24. Sonkusare S, Srinivasan K, Kaul C, Ramarao P: Effect of donepezil and
lercanidipine on memory impairment induced by intracerebroventricular
streptozotocin in rats. Life Sci 2005, 77:1–14.
25. Yamada K, Takayanagi M, Kamei H, Nagai T, Dohniwa M, Kobayashi K,
Yoshida S, Ohhara T, Takuma K, Nabeshima T: Effects of memantine and
donepezil on amyloid β-induced memory impairment in a delayed-
matching to position task in rats. Behav Brain Res 2005, 162:191–199.
26. Kamat PK, Tota S, Shukla R, Ali S, Najmi AK, Nath C: Mitochondrial
dysfunction: a crucial event in okadaic acid (ICV) induced memory
impairment and apoptotic cell death in rat brain. Pharmacol Biochem
Behav 2011, 100:311–319.
27. Su D, Zhao Y, Wang B, Xu H, Li W, Chen J, Wang X: Isoflurane-induced
spatial memory impairment in mice is prevented by the
acetylcholinesterase inhibitor donepezil. PLoS One 2011, 6:e27632.
28. Waite JJ, Chen AD: Differential changes in rat cholinergic parameters
subsequent to immunotoxic lesion of the basal forebrain nuclei.
Brain Res 2001, 918:113–120.
29. Petrosini L, De Bartolo P, Cutuli D: Neurotoxic effects, mechanisms and
outcome of 192-IgG-saporin. In Handbook of Neurotoxicity. Edited by Kostrzewa
RM. New York: Springer-Verlag; 2013. in press. ISBN: 978-1-4614-5835-7.
30. Brudzynski SM: Communication of adult rats by ultrasonic vocalization:
biological, sociobiological, and neuroscience approaches. ILAR J 2009,
50:43–50.
31. Brudzynski SM, Holland G: Acoustic characteristics of air puff-induced 22-kHz
alarm calls in direct recordings. Neurosci Biobehav Rev 2005, 29:1169–1180.
32. Wöhr M, Borta A, Schwarting RK: Overt behavior and ultrasonic
vocalization in a fear conditioning paradigm: a dose–response study in
the rat. Neurobiol Learn Mem 2005, 84:228–240.
33. Cavallucci V, Berretta N, Nobili A, Nisticò R, Mercuri NB, D’Amelio M:
Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse
model of Alzheimer’s disease. Neuromolecular Med 2013, 15:541–548.
34. Coleman PD, Yao PJ: Synaptic slaughter in Alzheimer’s disease.
Neurobiol Aging 2003, 24:1023–1027.
35. D’Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A,
Diamantini A, De Zio D, Carrara P, Battistini L, Moreno S, Bacci A,
Ammassari-Teule M, Marie H, Cecconi F: Caspase-3 triggers early synaptic
dysfunction in a mouse model of Alzheimer’s disease. Nat Neurosci 2011,
14:69–76.
36. D’Amelio M, Sheng M, Cecconi F: Caspase-3 in the central nervous
system: beyond apoptosis. Trends Neurosci 2012, 35:700–709.
37. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. 4th edition.
San Diego, CA: Academic Press; 1998.
38. Frick KM, Kim JJ, Baxter MG: Effects of complete immunotoxin lesions of
the cholinergic basal forebrain on fear conditioning and spatial learning.
Hippocampus 2004, 14:244–254.
39. Save E, Poucet B, Foreman N, Buhot MC: Object exploration and
reactions to spatial and nonspatial changes in hooded rats followingdamage to parietal cortex or hippocampal formation. Behav Neurosci
1992, 106:447–456.
40. Ricceri L, Cutuli D, Venerosi A, Scattoni ML, Calamandrei G: Neonatal basal
forebrain cholinergic hypofunction affects ultrasonic vocalizations and
fear conditioning responses in preweaning rats. Behav Brain Res 2007,
183:111–117.
41. Cutuli D, Foti F, Mandolesi L, De Bartolo P, Gelfo F, Federico F, Petrosini L:
Cognitive performance of healthy young rats following chronic
donepezil administration. Psychopharmacology (Berl) 2008, 197:661–673.
42. De Bartolo P, Cutuli D, Ricceri L, Gelfo F, Foti F, Laricchiuta D, Scattoni ML,
Calamandrei G, Petrosini L: Does age matter? Behavioral and neuro-
anatomical effects of neonatal and adult basal forebrain cholinergic
lesions. J Alzheimers Dis 2010, 20:207–227.
43. Ricceri L: Behavioral patterns under cholinergic control during
development: lessons learned from the selective immunotoxin 192 IgG
saporin. Neurosci Biobehav Rev 2003, 27:377–384.
44. Knox D, Berntson GG: Effect of nucleus basalis magnocellularis
cholinergic lesions on fear-like and anxiety-like behavior. Behav Neurosci
2006, 120:307–312.
45. Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F: Cognitive
enhancing properties and tolerability of cholinergic agents in mice:
a comparative study of nicotine, donepezil, and SIB-1553A, a
subtype-selective ligand for nicotinic acetylcholine receptors.
Neuropsychopharmacology 2003, 28:1235–1246.
46. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y: Donepezil, a centrally acting
acetylcholinesterase inhibitor, alleviates learning deficits in
hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 2000,
22:89–95.
47. Savage S, Kehr J, Olson L, Mattsson A: Impaired social interaction and
enhanced sensitivity to phencyclidine-induced deficits in novel object
recognition in rats with cortical cholinergic denervation. Neuroscience 2011,
195:60–69.
48. Buhot MC, Rage P, Segu L: Changes in exploratory behaviour of hamsters
following treatment with 8-hydroxy-2-(di-n-propylamino)tetralin.
Behav Brain Res 1989, 35:163–179.
49. Bussey TJ, Saksida LM: Object memory and perception in the medial
temporal lobe: an alternative approach. Curr Opin Neurobiol 2005,
15:730–737.
50. Riedel G, Kang SH, Choi DY, Platt B: Scopolamine-induced deficits in social
memory in mice: reversal by donepezil. Behav Brain Res 2009, 204:217–225.
51. Rockwood K, Graham JE, Fay S, ACADIE Investigators: Goal setting and
attainment in Alzheimer’s disease patients treated with donepezil.
J Neurol Neurosurg Psychiatry 2002, 73:500–507.
52. Mattsson A, Lindqvist E, Ogren SO, Olson L: Increased phencyclidine-
induced hyperactivity following cortical cholinergic denervation.
Neuroreport 2005, 16:1815–1819.
53. Mattsson A, Olson L, Svensson TH, Schilström B: Cortical cholinergic
deficiency enhances amphetamine-induced dopamine release in the
accumbens but not striatum. Exp Neurol 2007, 208:73–79.
54. Louneva N, Cohen JW, Han LY, Talbot K, Wilson RS, Bennett DA, Trojanowski JQ,
Arnold SE: Caspase-3 is enriched in postsynaptic densities and increased in
Alzheimer’s disease. Am J Pathol 2008, 173:1488–1495.
doi:10.1186/alzrt215
Cite this article as: Cutuli et al.: Neuroprotective effects of donepezil
against cholinergic depletion. Alzheimer's Research & Therapy 2013 5:50.
